Prognostic value of transglutaminase 2 in non-small cell lung cancer patients

Zhu Chihong; Ling Yutian; Wan Danying; Jiang Ruibin; Sheng Huaying; Gu Linhui; Feng Jianguo

doi:10.18632/oncotarget.17374

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Prognostic value of transglutaminase 2 in non-small cell lung cancer patients

Zhu Chihong, Ling Yutian, Wan Danying, Jiang Ruibin, Sheng Huaying, Gu Linhui _ and Feng Jianguo

PDF | HTML | How to cite

Oncotarget. 2017; 8:45577-45584. https://doi.org/10.18632/oncotarget.17374

Metrics: PDF 1690 views | HTML 2534 views | ?

Abstract

Zhu Chihong1,*, Ling Yutian1,*, Wan Danying1, Jiang Ruibin1, Sheng Huaying1, Gu Linhui1,2 and Feng Jianguo1,2

1Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China

2Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Hangzhou, Zhejiang 310022, China

*These authors have contributed equally to this work

Correspondence to:

Gu Linhui, email: [email protected]

Feng Jianguo, email: [email protected]

Keywords: TG2, NSCLC, prognosis

Abbreviations: TG2: Transglutaminase 2; NSCLC: non-small cell lung cancer

Received: November 23, 2016 Accepted: February 20, 2017 Published: April 24, 2017

ABSTRACT

Transglutaminase 2 (TG2) plays important roles in cell survival and cancer progression. In this study, we examined TG2 expression in specimen of 194 patients diagnosed with non-small cell lung cancer (NSCLC), and found that the TG2 gene expression was significantly higher in lung cancer tissues as compared to paired incisal marginal tissues or normal tissues. Our data revealed that patients with lower level of TG2 expression detected in cancer tissues had longer disease free survival and overall survival as compared to the patients with higher TG2 expression. We also found that TG2 expression level correlated to NSCLC recurrence. These results suggest a potential prognosis impact of TG2 for NSCLC patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17374

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Prognostic value of transglutaminase 2 in non-small cell lung cancer patients

Abstract